Ma Ning, Shan Yongli, Liao Baojian, Kong Guanyi, Wang Cheng, Huang Ke, Zhang Hui, Cai Xiujuan, Chen Shubin, Pei Duanqing, Chen Nansheng, Pan Guangjin
From the Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Wuhan Frasergen Bioinformatics Company Limited, Wuhan 430075, China, and.
J Biol Chem. 2015 May 8;290(19):12079-89. doi: 10.1074/jbc.M114.624999. Epub 2015 Mar 20.
The generation of personalized induced pluripotent stem cells (iPSCs) followed by targeted genome editing provides an opportunity for developing customized effective cellular therapies for genetic disorders. However, it is critical to ascertain whether edited iPSCs harbor unfavorable genomic variations before their clinical application. To examine the mutation status of the edited iPSC genome and trace the origin of possible mutations at different steps, we have generated virus-free iPSCs from amniotic cells carrying homozygous point mutations in β-hemoglobin gene (HBB) that cause severe β-thalassemia (β-Thal), corrected the mutations in both HBB alleles by zinc finger nuclease-aided gene targeting, and obtained the final HBB gene-corrected iPSCs by excising the exogenous drug resistance gene with Cre recombinase. Through comparative genomic hybridization and whole-exome sequencing, we uncovered seven copy number variations, five small insertions/deletions, and 64 single nucleotide variations (SNVs) in β-Thal iPSCs before the gene targeting step and found a single small copy number variation, 19 insertions/deletions, and 340 single nucleotide variations in the final gene-corrected β-Thal iPSCs. Our data revealed that substantial but different genomic variations occurred at factor-induced somatic cell reprogramming and zinc finger nuclease-aided gene targeting steps, suggesting that stringent genomic monitoring and selection are needed both at the time of iPSC derivation and after gene targeting.
生成个性化诱导多能干细胞(iPSC),随后进行靶向基因组编辑,为开发针对遗传疾病的定制有效细胞疗法提供了机会。然而,在其临床应用之前,确定编辑后的iPSC是否存在不利的基因组变异至关重要。为了检查编辑后的iPSC基因组的突变状态并追踪不同步骤中可能突变的起源,我们从携带β-珠蛋白基因(HBB)纯合点突变的羊膜细胞中生成了无病毒iPSC,该突变导致严重的β-地中海贫血(β-Thal),通过锌指核酸酶辅助基因靶向纠正了两个HBB等位基因中的突变,并通过用Cre重组酶切除外源耐药基因获得了最终的HBB基因校正iPSC。通过比较基因组杂交和全外显子测序,我们在基因靶向步骤之前的β-Thal iPSC中发现了七个拷贝数变异、五个小插入/缺失和64个单核苷酸变异(SNV),并在最终基因校正的β-Thal iPSC中发现了一个小拷贝数变异、19个插入/缺失和340个单核苷酸变异。我们的数据表明,在因子诱导的体细胞重编程和锌指核酸酶辅助基因靶向步骤中发生了大量但不同的基因组变异,这表明在iPSC衍生时和基因靶向后都需要严格的基因组监测和筛选。